Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* fasting C-peptide \>0.12 nmol/l~* within three weeks of diagnosis of type 1 diabetes~Exclusion Criteria:~* body mass index (BMI) \>30~* unstable cardiovascular status incl. New York Heart Association (NYHA) class III/IV~* patients with known or previous malignancy~* active infections incl. serological evidence of infection with HIV, Treponema pallidum, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.~* immune suppressive treatment~* women being pregnant or nursing, or women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- sham transplantation of mesenchymal stem cells (Type: PLACEBO_COMPARATOR): control arm with sham transplantation
- autologous mesenchymal stem cell transplantation (Type: ACTIVE_COMPARATOR): Active arm with transplantation of cells

Based on this trial design, predict the completion outcome and termination type (if applicable).